S plex human ifnα2a kit

Manufactured by Mesoscale

The S-plex Human IFNα2a kit is a quantitative immunoassay designed to measure the concentration of human interferon alpha 2a (IFNα2a) in biological samples. The kit utilizes the company's proprietary S-plex technology to provide precise and sensitive detection of the target analyte.

Automatically generated - may contain errors

Lab products found in correlation

Bio plex manager 6, by Bio-Rad (2 mentions) R plex human calprotectin antibody set, by Mesoscale (2 mentions) Bio plex 200 system, by Bio-Rad (2 mentions)

3 protocols using s plex human ifnα2a kit

Multiplex Cytokine Profiling of Serum

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum samples were centrifuged for 15 min at 1000 × g, diluted 1:4, then monitored using the Bio-Plex ProTM Human Chemokine Panel 40-plex Assay (Bio-rad, ref: 171AK99MR2) according to the manufacturer’s instructions. 40-plex cytokines and chemokines provided are CCL1, CCL11, CCL13, CCL15, CCL17, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL3, CCL7, CCL8, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL16, CXCL2, CXCL5, CXCL6, CXCL8, CXCL9, GM-CSF, IFN-γ, IL-10, IL-16, IL-1β, IL-2, IL-4, IL-6, MIF, TNF- α. Acquisitions and analyses were performed on a Bio-Plex 200 system (Bio-rad) and a Bio-Plex Manager 6.1 Software (Bio-rad), respectively. Soluble Calprotectin (diluted 1:100) and IFN-α2a were analyzed using a R-plex Human Calprotectin Antibody Set (Meso Scale Discovery, ref: F21YB-3) and the ultrasensitive assay S-plex Human IFN-α2a kit (Meso Scale Discovery, ref: K151P3S-1), respectively, following manufacturer’s instructions. Acquisitions and analyses of soluble Calprotectin and IFN-α2a were performed on a MESO™ QuickPlex SQ120 reader and the MSD’s Discovery Workbench 4.0. Each serum sample was assayed twice with the average value taken as the final result.

Goubet A.G., Dubuisson A., Geraud A., Danlos F.X., Terrisse S., Silva C.A., Drubay D., Touri L., Picard M., Mazzenga M., Silvin A., Dunsmore G., Haddad Y., Pizzato E., Ly P., Flament C., Melenotte C., Solary E., Fontenay M., Garcia G., Balleyguier C., Lassau N., Maeurer M., Grajeda-Iglesias C., Nirmalathasan N., Aprahamian F., Durand S., Kepp O., Ferrere G., Thelemaque C., Lahmar I., Fahrner J.E., Meziani L., Ahmed-Belkacem A., Saïdani N., La Scola B., Raoult D., Gentile S., Cortaredona S., Ippolito G., Lelouvier B., Roulet A., Andre F., Barlesi F., Soria J.C., Pradon C., Gallois E., Pommeret F., Colomba E., Ginhoux F., Kazandjian S., Elkrief A., Routy B., Miyara M., Gorochov G., Deutsch E., Albiges L., Stoclin A., Gachot B., Florin A., Merad M., Scotte F., Assaad S., Kroemer G., Blay J.Y., Marabelle A., Griscelli F., Zitvogel L, & Derosa L. (2021). Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death and Differentiation, 28(12), 3297-3315.

+ Open protocol

+ Expand

Multiplexed Biomarker Analysis of Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma samples were centrifuged for 15 min at 1000 g, diluted 1:4, then monitored using the Angiogenesis Panel 1 (human) (Meso Scale Discovery, ref.: K151P3S-1), Chemokines Panel 1, Proinflammatory Panel 1, Cytokine Panel 1 (Meso Scale Discovery, ref.: K151A9H-1), the ultra-sensitive assay S-plex Human IFNα2a kit (Meso Scale Discovery, ref.: K151P3S-1), Human PD-1 and PD-L1 antibody sets (Meso Scale Discovery, ref.: F214A-3 & F214C-3, respectively) following manufacturer’s instructions. Acquisitions and analyses were performed on a MESO™ QuickPlex SQ120 reader and the MSD’s Discovery Workbench 4.0. Each plasma sample was assayed twice with the average value taken as the result.

Baldini C., Danlos F.X., Varga A., Texier M., Halse H., Mouraud S., Cassard L., Champiat S., Signolle N., Vuagnat P., Martin-Romano P., Michot J.M., Bahleda R., Gazzah A., Boselli L., Bredel D., Grivel J., Mohamed-Djalim C., Escriou G., Grynszpan L., Bigorgne A., Rafie S., Abbassi A., Ribrag V., Postel-Vinay S., Hollebecque A., Susini S., Farhane S., Lacroix L., Parpaleix A., Laghouati S., Zitvogel L., Adam J., Chaput N., Soria J.C., Massard C, & Marabelle A. (2022). Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. Journal of Experimental & Clinical Cancer Research : CR, 41, 217.

+ Open protocol

+ Expand

Multiplex Plasma Cytokine Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma samples (Table S6) were centrifuged for 15 min at 1,000 g, diluted 1:4, then monitored using the Bio-Plex Pro™ Human Chemokine Panel 40-plex Assay (Bio-rad, ref: 171AK99MR2) according to the manufacturer’s instructions. 40-plex cytokines and chemokines provided are: CCL1, CCL11, CCL13, CCL15, CCL17, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL3, CCL7, CCL8, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL16, CXCL2, CXCL5, CXCL6, CXCL8, CXCL9, GM-CSF, IFNα, IL-10, IL-16, IL-1b, IL-2, IL-4, IL-6, MIF, TNFa. Acquisitions and analyses were performed on a Bio-Plex 200 system (Bio-rad) and a Bio-Plex Manager 6.1 Software (Bio-rad), respectively. Soluble Calprotectin (diluted 1:100) and IFNα2a were analyzed using a R-plex Human Calprotectin Antibody Set (Meso Scale Discovery, ref: F21YB-3) and the ultra-sensitive assay S-plex Human IFNα2a kit (Meso Scale Discovery, ref: K151P3S-1), respectively, following manufacturer’s instructions. Acquisitions and analyses of soluble Calprotectin and IFNα were performed on a MESO QuickPlex SQ120 reader and the MSD’s Discovery Workbench 4.0. Each plasma sample was assayed twice with the average value taken as the final result. Data representation was performed with software R v3.3.3 using tidyverse, dplyr, ggplot2, ggpubr, pheatmap, corrplot or Hmisc packages.

Silvin A., Chapuis N., Dunsmore G., Goubet A.G., Dubuisson A., Derosa L., Almire C., Hénon C., Kosmider O., Droin N., Rameau P., Catelain C., Alfaro A., Dussiau C., Friedrich C., Sourdeau E., Marin N., Szwebel T.A., Cantin D., Mouthon L., Borderie D., Deloger M., Bredel D., Mouraud S., Drubay D., Andrieu M., Lhonneur A.S., Saada V., Stoclin A., Willekens C., Pommeret F., Griscelli F., Ng L.G., Zhang Z., Bost P., Amit I., Barlesi F., Marabelle A., Pène F., Gachot B., André F., Zitvogel L., Ginhoux F., Fontenay M, & Solary E. (2020). Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell, 182(6), 1401-1418.e18.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!